Sequential myeloablative autologous stem cell transplantation and reduced intensity allogeneic hematopoietic cell transplantation is safe and feasible in children, adolescents and young adults with poor-risk refractory or recurrent Hodgkin and non-Hodgkin lymphoma

Prakash Satwani(Pediatrics and Genetics), Mitchell S. Cairo(New York Medical College), Lauren Harrison(Gloucestershire Hospitals NHS Foundation Trust), Monica Bhatia(Columbia University Irving Medical Center), S. Foley(New York Medical College), Olga Militano(New York Medical College), Zhezhen Jin, Jean Sosna(Columbia University), Joanne Kurtzberg(Duke University), Sonali Chaudhury(Northwestern University), Julie‐An Talano(Dana-Farber Cancer Institute), James H. Garvin(Columbia University Irving Medical Center), Paul L. Martin(Duke University), Margaret Peterson(Duke University), D. George(Columbia University), Erin Morris(New York Medical College)
Leukemia
June 18, 2014
10.1038/leu.2014.194
Cited by 53

Related Papers

Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
|New England Journal of Medicine|2018|5.7k
Guidelines for the Management of Pediatric and Adult Tumor Lysis Syndrome: An Evidence-Based Review
|Journal of Clinical Oncology|2008|794
Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation
|Blood|2010|477
Results of the randomized international FAB/LMB96 trial for intermediate risk B-cell non-Hodgkin lymphoma in children and adolescents: it is possible to reduce treatment for the early responding patients
|Blood|2006|431
Three-Year Update of Tisagenlecleucel in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia in the ELIANA Trial
|Journal of Clinical Oncology|2022|369